Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigefumi Morimoto

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 25, 2010
[Construction of a system for proper TS-1 application]Sayaka Azuma, Shigefumi Morimoto, Kunihiko Kagawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[Study of a relationship between a change in the urinary uracil value after a S-1 long-term administration and the recurrence of stomach cancer]Shigefumi Morimoto, Takeshi Tsuji, Yoshiharu Shono, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2011
[Efforts toward qualitative and quantitative improvements of cancer clinical trials at regional designated cancer care hospitals-through full support for cancer clinical trials by oncology pharmacy specialist and data manager]Shigefumi Morimoto, Ryoko Inoue, Yoshiharu Shono, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 19, 2009
Significance of urinary glucaric acid measurement and its application to paclitaxel therapyShigefumi Morimoto, Toshiki Koda, Tomoki Suidzu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 16, 2011
[Etiology and management of venous pain during intravenous administration of oxaliplatin]Kazuyo Matsuyama, Hideyuki Mishima, Hiroyuki Ueno, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals]Noriaki Kitada, Satoko Morita, Shigefumi Morimoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 3, 2008
[Determining S-1 dosage at hospitals prioritizing cancer chemotherapy]Shigefumi Morimoto, Noriaki Kitada, Setsuko Anami, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochlorideShigefumi Morimoto, Ichiro Matsuura, Yoshiharu Shono, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 23, 2009
[Palliative care team in National Hospital Organization Osaka Minami Medical Center]Takashi Hama, Suguru Yamamoto, Satoru Sakaguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2008
[Equalization of spread of breast cancer chemotherapy regimen at general hospitals--with EC and FEC regimens]Noriaki Kitada, Takahiro Nakayama, Satoko Morita, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 25, 2010
[Construction of a system for proper TS-1 application]Sayaka Azuma, Shigefumi Morimoto, Kunihiko Kagawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[Study of a relationship between a change in the urinary uracil value after a S-1 long-term administration and the recurrence of stomach cancer]Shigefumi Morimoto, Takeshi Tsuji, Yoshiharu Shono, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2011
[Efforts toward qualitative and quantitative improvements of cancer clinical trials at regional designated cancer care hospitals-through full support for cancer clinical trials by oncology pharmacy specialist and data manager]Shigefumi Morimoto, Ryoko Inoue, Yoshiharu Shono, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 19, 2009
Significance of urinary glucaric acid measurement and its application to paclitaxel therapyShigefumi Morimoto, Toshiki Koda, Tomoki Suidzu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 16, 2011
[Etiology and management of venous pain during intravenous administration of oxaliplatin]Kazuyo Matsuyama, Hideyuki Mishima, Hiroyuki Ueno, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals]Noriaki Kitada, Satoko Morita, Shigefumi Morimoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 3, 2008
[Determining S-1 dosage at hospitals prioritizing cancer chemotherapy]Shigefumi Morimoto, Noriaki Kitada, Setsuko Anami, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochlorideShigefumi Morimoto, Ichiro Matsuura, Yoshiharu Shono, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 23, 2009
[Palliative care team in National Hospital Organization Osaka Minami Medical Center]Takashi Hama, Suguru Yamamoto, Satoru Sakaguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 19, 2008
[Equalization of spread of breast cancer chemotherapy regimen at general hospitals--with EC and FEC regimens]Noriaki Kitada, Takahiro Nakayama, Satoko Morita, et al.
Pageof 1